Acorah Software Products - Accounts Production 16.8.200 false true false true No description of principal activity 1 January 2024 31 December 2024 31 December 2024 13780297 Mr Bilal Maravia iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 13780297 2023-12-31 13780297 2024-12-31 13780297 2024-01-01 2024-12-31 13780297 frs-core:CurrentFinancialInstruments 2024-12-31 13780297 frs-bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 13780297 frs-bus:FilletedAccounts 2024-01-01 2024-12-31 13780297 frs-bus:Micro-entities 2024-01-01 2024-12-31 13780297 frs-bus:AuditExempt-NoAccountantsReport 2024-01-01 2024-12-31 13780297 frs-bus:Director1 2024-01-01 2024-12-31
Registered number: 13780297
Rayan Pharmaceuticals Ltd
Unaudited Financial Statements
For The Year Ended 31 December 2024
Balance Sheet
Registered number: 13780297
2024
£
Fixed assets 3,193
Current assets 147,035
Prepayments and accrued income 8,029
Creditors: Amounts Falling Due Within One Year (156,352 )
NET CURRENT LIABILITIES (1,288 )
TOTAL ASSETS LESS CURRENT LIABILITIES 1,905
Accruals and deferred income (500 )
NET ASSETS 1,405
CAPITAL AND RESERVES 1,405

Notes

1. General Information
Rayan Pharmaceuticals Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 13780297 . The registered office is 20-22 Wenlock Road, London, N1 7GU.
2. Average Number of Employees
Average number of employees, including directors, during the year was: 2
2
For the year ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
On behalf of the board
Mr Bilal Maravia
Director
31/12/2025